Romiplostim

CHEMBL1201832 Phase 4 已批准 Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A thrombopoietin receptor agonist given as a weekly injection to stimulate platelet production in adults with chronic immune thrombocytopenia who have not responded to other treatments. It mimics the natural hormone thrombopoietin to signal the bone marrow to produce more platelets.

治疗领域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A thrombopoietin receptor agonist given as a weekly injection to stimulate platelet production in adults with chronic immune thrombocytopenia who have not responded to other treatments. It mimics the natural hormone thrombopoietin to signal the bone marrow to produce more platelets.

Yes, Romiplostim is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201832. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.